Pipeline Watch/R&D Round Up
22 January 2010
This week’s bumper Pipeline Watch covers the two weeks over Christmas and New Year and records the traditional flurry of activity as companies seek to complete regulatory filings by year-end. Among those products being filed in their first markets were two new candidates for obesity – Arena’s...
Please Login to read the full article.
22 January 2010
This week’s bumper Pipeline Watch covers the two weeks over Christmas and New Year and records the traditional flurry of activity as companies seek to complete regulatory filings by year-end. Among those products being filed in their first markets were two new candidates for obesity – Arena’s...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US FDA accepts Vivus NDA resubmission for obesity drug
- Vivus narrows indication for Qnexa obesity drug to FDA to enable Q2 2012 approval
- Arena hopes lower concentration of obesity drug in human brain will reassure FDA
- A year in pharma and biotech R&D: Healthy numbers belie lack of novelty
EVENTS
09 February 2012
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
